Literature DB >> 12426517

Disposition of nasal, intravenous, and oral methadone in healthy volunteers.

Ola Dale1, Christine Hoffer, Pamela Sheffels, Evan D Kharasch.   

Abstract

OBJECTIVE: Nasal administration of many opioids demonstrates rapid uptake and fast onset of action. Nasal administration may be an alternative to intravenous and oral administration of methadone and was therefore studied in human volunteers.
METHODS: The study was approved by the Institutional Review Board of the University of Washington, Seattle. Eight healthy volunteers (6 men and 2 women) aged 19 to 33 years were enrolled after informed written consent was obtained. Subjects received 10 mg methadone hydrochloride nasally, orally, or intravenously on 3 separate occasions in a crossover design. Nasal methadone (50 mg/mL in aqueous solution) was given as a 100-microL spray in each nostril (Pfeiffer BiDose sprayer). Blood samples for liquid chromatography-mass spectrometry analyses of methadone and the metabolite 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium were drawn for up to 96 hours. The methadone effect was measured by noninvasive infrared pupilometry coincident with blood sampling.
RESULTS: Nasal uptake of methadone was rapid, with maximum plasma concentrations occurring within 7 minutes. The maximum effects of intravenous, nasal, and oral methadone, on the basis of dark-adapted pupil diameter, were reached in about 15 minutes, 30 minutes, and 2 hours, respectively. The respective durations were 24, 10, and 8 hours. Both nasal and oral bioavailabilities were 0.85. Subjects reported that nasal methadone caused a burning sensation.
CONCLUSIONS: Nasal administration of methadone results in rapid absorption and onset of effect and high bioavailability, which was greater than that reported for other nasal opioids, with a similar duration of effect. Nasal administration may be an alternative route of methadone administration; however, improved formulations are desirable to reduce nasal irritation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426517     DOI: 10.1067/mcp.2002.128386

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility.

Authors:  Robert K Vinson
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

2.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  Pharmacokinetics of a new, nasal formulation of naloxone.

Authors:  Ida Tylleskar; Arne Kristian Skulberg; Turid Nilsen; Sissel Skarra; Phatsawee Jansook; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2017-01-31       Impact factor: 2.953

Review 4.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

5.  Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.

Authors:  Arne Kristian Skulberg; Ida Tylleskar; Turid Nilsen; Sissel Skarra; Øyvind Salvesen; Trond Sand; Thorsteinn Loftsson; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2018-03-22       Impact factor: 2.953

6.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

7.  Bioavailabilities of rectal and oral methadone in healthy subjects.

Authors:  Ola Dale; Pamela Sheffels; Evan D Kharasch
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

8.  Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP).

Authors:  Patrick A Forcelli; Jill R Turner; Bridgin G Lee; Thao T Olson; Teresa Xie; Yingxian Xiao; Julie A Blendy; Kenneth J Kellar
Journal:  Neuropharmacology       Date:  2015-09-11       Impact factor: 5.250

9.  Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients.

Authors:  Brooks T McPhail; Chie Emoto; Tsuyoshi Fukuda; Dawn Butler; Jason R Wiles; Henry Akinbi; Alexander A Vinks
Journal:  J Clin Pharmacol       Date:  2019-12-09       Impact factor: 3.126

10.  Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?

Authors:  Kristin Moksnes; Olav M Fredheim; Pål Klepstad; Stein Kaasa; Anders Angelsen; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2008-01-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.